Omics Techniques in Fatty Liver Disease

Precision Medicine in Fatty Liver Disease: How to Identify the Patient Who Develops Steatohepatitis Using Omics Techniques

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05907408

Enrollment

Registered

2023-06-18

Start date

2023-07-01

Completion date

2023-12-31

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease

Keywords

nonalcoholic fat liver disease, NASH, metabolic fat liver disease, risk factors, noninvasive markers, transcriptomics, metabolomics, proteomics, liver fibrosis

Brief summary

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Metabolic syndrome * Liver steatosis detected on transient hepatic elastography performed in the last 12 months * Steatosis with or without fibrosis confirmed histologically in a liver biopsy performed in the last 12 months

Exclusion criteria

* Concurrent liver disease (other than NAFLD) * Chronic or prolonged use of any potential hepatotoxic drug or substance * HIV infection * Cancer (except basal cell carcinoma)

Design outcomes

Primary

Measure	Time frame	Description
Steatosis, without fibrosis or inflammation	12 months	Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation
Steatohepatitis, with fibrosis	12 months	Patients with non-alcoholic fatty liver disease presenting with steatosis and degree \>1 of liver fibrosis

Countries

Brazil

Contacts

Primary ContactGuilherme FM Rezende, MD PhD

guimottarezende@gmail.com55+21999976292

Backup ContactRegina CS Goldenberg, BSND PhD

rcoeli@biof.ufrj.br55+21999913066

Outcome results